Curis IncCRIS

Curis’s clinical team now has eleven active sites screening patients for the TakeAim CLL combination study of emavusertib (CA-4948) plus zanubrutinib, the company confirmed on 26 June 2026, and it still expects to dose the first five patients by the end of July 2026 with data to follow. The study is the single largest near-term catalyst for the company’s lead asset, but it carries no revenue promise yet; Curis’s last reported revenue from contracts with customers, excluding tax, was $0 in the quarter to 31 March 2026. (source: Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split, https://investors.curis.com/2026-06-26-Curis-Announces-Eleven-Active-Clinical-Sites-in-TakeAim-CLL-Study,-Reaffirms-Patient-Dosing-Guidance,-and-Reports-Stockholder-Approval-of-Reverse-Stock-Split)

Curis describes its pipeline programmes-CA-170, a first-in-class suppressor of VISTA, and CA-327, a first-in-class suppressor of TIM3-as immuno-oncology assets with differentiated mechanisms. The company’s own pages spell out the science in detail, yet the financial ledger remains stubbornly silent: Curis has no approved products, no royalty revenues, and no marketed drugs generating sales. The operating reality is a loss-making biotech burning cash while it builds the evidence base for emavusertib and its pipeline companions. (source: CA-170 - Curis, Inc, https://www.curis.com/pipeline/ca-170/; CA-327 - Curis, Inc, https://www.curis.com/pipeline/ca-327/)

For the quarter ended 31 March 2026, Curis reported net loss attributable to parent of $24.2 million, operating loss of $11.5 million, and a negative $9.0 million in net cash used in operating activities. Diluted loss per share was $1.25 on 19.4 million diluted shares outstanding. Total assets stood at $29.7 million against liabilities of $17.0 million, leaving $12.7 million in stockholders’ equity. Cash and cash equivalents at quarter-end were $15.0 million, a figure that must fund both the clinical build-out and the company’s day-to-day costs. Revenue from contracts with customers, excluding tax, remained at $0. (source: SEC EDGAR CURIS INC 10-Q for period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1108205/000110820526000096/xslF345X06/wk-form4_1783627959.xml)

The company’s market narrative rests on the promise of emavusertib and its pipeline, but the filing record shows no revenue, no near-term product revenue, and no approvals. Shareholders recently approved a reverse stock split, a cosmetic move that can tidy a share price but does nothing to address the $24.2 million quarterly loss or the $9.0 million quarterly cash burn. The split is optics, not economics, and it leaves the core tension unchanged: Curis still needs a paying customer or a licensing deal before the cash runway runs short. (source: SEC EDGAR CURIS INC DEF 14A, https://www.sec.gov/Archives/edgar/data/1108205/000110820526000091/xslF345X06/wk-form4_1783627918.xml)

What we do not know is whether the TakeAim CLL study will deliver the promised dosing by July 2026 or whether the data will show sufficient safety and efficacy to attract a partner or justify a pivotal programme. Curis’s cash position gives it runway, but runway alone does not guarantee success. The next catalyst is the patient-dosing milestone; anything less than five patients dosed by month-end would raise questions about the timeline. Until then, the balance sheet remains the primary source of truth. (source: Curis SEC submissions JSON, https://data.sec.gov/submissions/CIK0001108205.json)